Title |
Ezetimibe therapy: mechanism of action and clinical update
|
---|---|
Published in |
Vascular Health and Risk Management, July 2012
|
DOI | 10.2147/vhrm.s33664 |
Pubmed ID | |
Authors |
Binh An P Phan, Thomas D Dayspring, Peter P Toth |
Abstract |
The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in the primary and secondary prevention of cardiovascular events. Although statin therapy is the mainstay for LDL-C lowering, a significant percentage of patients prescribed these agents either do not achieve targets with statin therapy alone or have partial or complete intolerance to them. For such patients, the use of adjuvant therapy capable of providing incremental LDL-C reduction is advised. One such agent is ezetimibe, a cholesterol absorption inhibitor that targets uptake at the jejunal enterocyte brush border. Its primary target of action is the cholesterol transport protein Nieman Pick C1 like 1 protein. Ezetimibe is an effective LDL-C lowering agent and is safe and well tolerated. In response to significant controversy surrounding the use and therapeutic effectiveness of this drug, we provide an update on the biochemical mechanism of action for ezetimibe, its safety and efficacy, as well as the results of recent randomized studies that support its use in a variety of clinical scenarios. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 18% |
Japan | 1 | 6% |
Unknown | 13 | 76% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 8 | 47% |
Practitioners (doctors, other healthcare professionals) | 6 | 35% |
Scientists | 3 | 18% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Chile | 1 | <1% |
United States | 1 | <1% |
China | 1 | <1% |
Unknown | 459 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 94 | 20% |
Student > Ph. D. Student | 41 | 9% |
Student > Master | 41 | 9% |
Researcher | 35 | 8% |
Other | 28 | 6% |
Other | 77 | 17% |
Unknown | 146 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 95 | 21% |
Pharmacology, Toxicology and Pharmaceutical Science | 55 | 12% |
Biochemistry, Genetics and Molecular Biology | 53 | 11% |
Agricultural and Biological Sciences | 40 | 9% |
Chemistry | 15 | 3% |
Other | 42 | 9% |
Unknown | 162 | 35% |